Provectus Biopharmaceuticals, Inc. — Balance Sheet Charts
8 snapshots of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Assets vs Liabilities
Cash Position Breakdown
Working Capital Components
Total Assets↓-30.7% -$309K
$698K
Current Assets↓-41.9% -$409K
$568K
Cash & Equivalents↓-18.3% -$56K
$251K
Receivables
—
Net PPE↓-38.3% -$2K
$3K
Intangibles
—
Total Liabilities↑+0.4% +$25K
$7M
Current Liabilities↓-1.1% -$78K
$7M
Account Payables↓-35.3% -$390K
$716K
Short-Term Debt
—
Stockholders Equity↓-5.7% -$339K
$-6M
Retained Earnings↓-2.1% -$5M
$-263M
Operating Lease ROU Asset↑+414.2% +$102K
$127K
Operating Lease Liability↑+403.2% +$102K
$127K
Accumulated Depreciation↑+1.6% +$2K
$120K
Total Debt Carrying Amount
—